简介：Thetitlecompoundchlorpropham(CASnumber:101-21-3,C10H12ClNO2,Mr=213.66)waspreparedbytheadditionreactionof3-chlorophenylisocyanatewithisopropanol.Spectraldata,IR,NMRandMS,werereported.ThispaperprovidessomerelatedinformationaboutRegulatoryStatus,ToxicologicalEffects,EcologicalEffectsandEnvironmentalFatealso.

简介：“FusionWorld”科技展示体验中心是英国设计公司METStudio为新加坡科技研究局（A＊Star）的科学工程委员会（SERC）所设计的,位于启汇城的办公地点，用于展示该委员会的精选技术作品，以吸引潜在的客户和启汇城内的学生购买群体。

简介：Performancesrequired:prospecttobeadoptedinDEMO.ShieldingforV.V.andTFCinITER.Designprinciples:thepeaktemperatureandstressshouldnotexceedtechnicallimits.Thestructureoftestblanketmodules(TBM)shouldbesimpleforeasyfabrication,andTBMshouldberobustforreliability.

简介：Ameloblastomaisabenignbutlocallyaggressiveodontogenieneoplasmthataccountsfor10%ofalltumorsarisinginthemandibleandmaxilla(1).Eightypercentofameloblastomasariseinthemandible,andtheyareusuallyfoundinyoungadults.Itfrequentlyrecursifnotadequatelyresected.Therefore,thestandardtherapyforthistumoriscompleteboneresectionwithanadequatemarginofsafety:marginalorsegmentalosteotomy.However,aestheticdeformities,functionalimpairmentsandpsychologicalimpairmentsafterradicalsurgeryforlargeameloblastoma,havebeenseriousissues(1).

简介：Apotentialdualinhibitor(4)forexogenousabsorptionandendogenicsynthesisofcholesterolwasdesignedbasedontheconjugationoftheβ-lactampharmacophoreofezetimibeandtheδ-lactonepharmacophoreofstatins.Themergerofezetimibeandstatin4wassynthesizedfromp-hydroxybenzaldehydethroughaten-steproute.1HNMRanalysisshowedexistenceoffourpairsofenantiomers(5.7:5.7:1:1,molarratio).Andcompound4wasfoundtolowertotalglucose(TG)levelinratserumviaahigh-cholesterolandhigh-fatfeedingexperiment.

简介：Objective:ToinvestigatetheeffectsofE7080andN5-(1-iminoethyl)-L-ornithinedihydrochloride(L-NIO)oncolorectalcanceraloneandincombination.Methods:HT29colorectalcancercelllinefromSapInstitutewasused.Real-timecellanalysis(xCELLigencesystem)wasperformedtodeterminetheeffectsofE7080andL-NIOoncolorectalcellproliferation.WhileapoptosiswasdeterminedwithAnnexinVstaining,andtheeffectofagentsonangiogenesiswasdeterminedwithchorioallantoicmembrane(CAM)model.Results:WefoundthatE7080hasastrongantiproliferativeeffectwithanhalfmaximuminhibitionofconcentration(IC50)valueof5.60×10–8mol/L.AlsoithasbeenobservedthatE7080showedantiangiogenicandapoptoticeffectsonHT29colorectalcancercells.AntiangiogenicscoresofE7080were1.2,1.0and0.6for100,10and1nmol/LE7080concentrations,respectively.Furthermore,apoptosishasbeendetectedin71%ofHT29colorectalcancercellsafteradministrationof100nmol/LE7080whichmayindicatestrongapoptoticeffect.MeanwhileadministrationofL-NIOalonedidnotshowanyeffect,butthecombinationofE7080withL-NIOincreasedtheantiproliferative,antiangiogenicandapoptoticeffectsofE7080.Conclusions:ResultsofthisstudyindicatethatE7080maybeagoodchoiceintreatmentofcolorectaltumors.FurthermoretheincreasedeffectsofE7080whencombinedwithL-NIOraisethepossibilitytousealowerdoseofE7080andthereforeavoid/minimizethesideeffectsobservedwithE7080.

简介：

简介：

简介：Thefastions,producedinD-3Hefusionplasma,arethe14.7MeVprotonsand3.6MeVαparticles.Becausetheirslowingdowntimesarefinite,therefore,theydevelopacertainamountofadditionalbeta(fir)whichhastobesupportedbythemagneticfield.

简介：Asthebasicconditionsforlaserinertialconfinementfusion（ICF）research,thetargetsarerequiredtobewellspecifiedandelaboratelyfabricated.Becauseofthecharacteristicsofthetargets,theresearchandfabricationprocessisasystematicallytoughtask,whichneedsfundamentalanddeepinsightsintofilmdeposition,mechanicalmachining,precisemeasurementandassembly,etc.Asaresult,knowledgeofmaterialscience,physics,mechanicalaswellaselectronicsisanecessityfortargetresearchers.Inthispaper,wegiveintroductionstothestateofartontargetfabricationforICFresearchatResearchCenterofLaserFusion（RCLF）inChina.

简介：AbstractBackground:Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.Methods:We carried out a 48-week, randomized, controlled, open-label non-inferiority trial at 12 sites in China. Adults on the World Health Organization (WHO)-recommended first-line treatment for >6 months with a plasma viral load >1000 copies/mL were enrolled and randomly assigned (1:1) to receive albuvirtide (once weekly) plus ritonavir-boosted lopinavir (ABT group) or the WHO-recommended second-line treatment (NRTI group). The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks. Non-inferiority was prespecified with a margin of 12%.Results:At the time of analysis, week 24 data were available for 83 and 92 patients, and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups, respectively. At 48 weeks, 80.4% of patients in the ABT group and 66.0% of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL, meeting the criteria for non-inferiority. For the per-protocol population, the superiority of albuvirtide over NRTI was demonstrated. The frequency of grade 3 to 4 adverse events was similar in the two groups; the most common adverse events were diarrhea, upper respiratory tract infections, and grade 3 to 4 increases in triglyceride concentration. Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.Conclusions:The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug. This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Trial registration:ClinicalTrials.gov Identifier: NCT02369965; https://www.clinicaltrials.gov.Chinese Clinical Trial Registry No. ChiCTR-TRC-14004276; http://www.chictr.org.cn/enindex.aspx

简介：

简介：

简介：

简介：

简介：AdeuteronpossessesacoulombpotentialbarrierwithmaximumUmax≈10^6eV(atro=1.51×10^-13cm)aroundhim.Soprerequisitetodirectcollideandexcitenuclearfusionreactionfortwodeuteronsistopenetratetoallofoppositebarrier.

简介：

简介：数据熔化，新研究域，是现代信息技术和许多另外的题目的集成和扩展。数据熔化概念被介绍，Dempster-Shafer证据推理被描述并且适用于油和煤气的察觉。方法的一个例子用数字模拟数据被显示出。处理结果显示数据熔化方法能广泛地在烃察觉被使用。

简介：Onthebasisofananalysisoftheerrorsourcesinmultibeamechosoundingsystem,adataprocessingmethodforcompensatingsystematicerrorsinmultibeamsurveyisproposed.Inordertoimprovetheaccuracyofoverallswath,adatafusiontechniqueusingsinglebeamsurveydataascontrolinformationforsinglebeamandmultibeamechosoundingisthenpresented.Somequestionsinvolvedinsolvingtheadjustmentproblem,suchasitsfeasibilityandthenumericalstability,arediscussedindetail,andatwo-stepadjustmentmethodissuggested.Finally,apracticalsurveydatasetisusedasacasestudytoprovetheefficiencyandreliabilityoftheproposedmethods.

简介：Theapplicationoflaserpulseswithpsecorshorterdurationenablesnonthermalefficientultrahighaccelerationofplasmablockswithhomogeneoushighionenergiesexceedingioncurrentdensitiesof1012Acm-2.Theeffectsofultrahighaccelerationofplasmablockswithhighenergyprotonbeamsareproposedformuonproductioninacompactmagneticfusiondevice.Theproposednewschemeconsistsofanignitionfusionsparkbymuoncatalyzedfusion（μCF）inasmallmirror-likeconfigurationwherelowtemperatureD–Tplasmaistrappedforadurationof1μs.Thisinitialfusionsparkproducessufficientalphaheatinginordertoinitiatethefusionprocessinthemaindevice.Theuseofamulti-fluidglobalparticleandenergybalancecodeallowsustofollowthetemporalevolutionofthereactionrateofthefusionprocessinthedevice.RecentprogressontheICANandIZESTprojectsforhighefficienthighpowerandhighrepetitionratelasersystemsallowsdevelopmentoftheproposeddeviceforcleanenergyproduction.Withtheproposedapproaches,experimentsonfusionnuclearreactionsandμCFprocesscanbeperformedinmagnetizedplasmasinexistingkJ/PWlaserfacilitiesastheGEKKO-LFEX,thePETALandtheORIONorinthenearfuturelaserfacilitiesastheELI-NPRomanianpillar.